Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy

The following presentations are scheduled at the 2017 ESGCT meeting:

• Michael Holmes, Ph.D., VP, Research, will present an overview of Sangamo's optimized zinc finger nuclease (ZFN) architectures for therapeutic genome editing.
  Title: New zinc finger nuclease architectures for precision genome engineering in the development of novel genomic therapies
  Invited Talk ? Friday, October 20^th

• Anthony Conway, Ph.D., Sangamo scientist, will present additional research data on ZFN-mediated in vivo genome editing using the Company's lipid nanoparticle delivery platform.
  Title: In vivo genome editing via non-viral delivery of zinc finger nucleases enables supraphysiological levels of therapeutic proteins and greater than 90% protein knockdown of multiple therapeutic gene targets via targeted integration and NHEJ, respectively, in wild type mice
  Oral Presentation ? Wednesday, October 18^th

• Marshall Huston, Ph.D., Sangamo scientist, will present an update on the Company's preclinical stage gene therapy program for Fabry disease.
  Title: Liver-based expression of the human alpha-galactosidase A gene in murine Fabry model results in continuous high, therapeutic levels of enzyme activity and effective substrate reduction
  Poster Presentation ? Wednesday, October 18^th

Webcasting services are not provided at this meeting.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

SOURCE Sangamo Therapeutics, Inc.